Table 1.
Baseline characteristics of the randomized study participants.
| Variables | All n = 78 |
Placebo n = 39 |
Sevelamer n = 39 |
p |
|---|---|---|---|---|
| Age (years) | 63 ± 13 | 63 ± 14 | 63 ± 13 | 0.918 |
| Male gender, n (%) | 55 (70.5%) | 28 (71.8%) | 27 (69.2%) | 0.804 |
| GFR MDRD (mL/min per 1.73 m2) | 27.0 ± 9.1 | 28.1 ± 9.9 | 25.4 ± 8.1 | 0.193 |
| Serum phosphorus (mmol/L) | 1.24 ± 0.17 | 1.25 ± 0.16 | 1.23 ± 0.18 | 0.705 |
| Serum calcium (mmol/L) | 2.34 ± 0.11 | 2.33 ± 0.11 | 2.35 ± 0.11 | 0.486 |
| Serum creatinine (µmol/L) | 234 ± 76 | 227 ± 75 | 241 ± 79 | 0.379 |
| Serum albumin (g/L) | 41.7 ± 3.4 | 41.5 ± 3.7 | 41.9 ± 3.1 | 0.645 |
| Serum intact PTH (pg/mL) | 97 (61; 127) | 103 (71; 141) | 91 (58; 123) | 0.169 |
| Serum total cholesterol (mmol/L) | 4.7 ± 1.1 | 4.7 ± 1.0 | 4.7 ± 1.2 | 0.522 |
| Serum LDL cholesterol (mmol/L) | 2.5 ± 1.0 | 2.4 ± 1.0 | 2.6 ± 1.0 | 0.430 |
| Serum indoxyl sulfate (µg/mL) * 0.53 ± 0.29 µg/mL in healthy adults # [23] |
3.57 (1.32; 6.31) | 3.45 (1.07; 5.61) | 4.26 (1.77; 7.35) | 0.119 |
| Serum p-cresyl sulfate (µg/mL) * 1.9 ± 1.3 µg/mL in healthy adults # [23] |
10.65 (6.05; 17.69) | 10.34 (5.12; 21.00) | 11.34 (7.82; 16.44) | 0.681 |
| Serum indole acetic acid (µg/mL) * 0.5 ± 0.3 µg/mL in healthy adults # [23] |
1.02 (0.58; 1.44) | 0.96 (0.59; 1.47) | 1.08 (0.57; 1.44) | 0.812 |
Data are quoted as the mean ± SD for normally distributed variables, the median (interquartile range) for non-normally distributed variables, or the number (percentage) for qualitative variables. GFR MDRD: Glomerular filtration rate estimated using the Modification of Diet in Renal Disease equation; FGF23, fibroblast growth factor 23; RU, relative units; PTH, parathyroid hormone. * Available for 72 patients (placebo group: n = 35; sevelamer group: n = 37). # [23].